trending Market Intelligence /marketintelligence/en/news-insights/trending/lrxfzoow4bdf0c-onik7zq2 content esgSubNav
In This List

Aradigm to delist from Nasdaq

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Aradigm to delist from Nasdaq

Aradigm Corp.'s common stock will be suspended from Nasdaq trading on Sept. 14.

The delisting comes after Aradigm failed to regain compliance with the exchange's $35 million minimum market value of listed securities. Aradigm received the noncompliance notice in March, and had until Sept. 4 to regain compliance.

Aradigm may request a hearing to appeal the delisting, and stay the suspension. The company said it is evaluating available options to regain compliance.

Hayward, Calif.-based Aradigm develops drugs for the prevention and treatment of severe respiratory diseases.